KiraGen Bio is engineering the next generation of cancer immunotherapies to overcome the barriers that have limited CAR-T success in solid tumors.

While CAR-T therapies have transformed treatment in blood cancers, solid tumors remain largely resistant due to the immunosuppressive tumor microenvironment (TME). At KiraGen, we use AI-guided, multiplex gene editing combinations to give cell therapies the equivalent of noise-cancelling headphones—filtering out tumor microenvironment suppression while preserving their natural function. This approach is designed to enable more effective, durable responses in the most challenging blood and solid cancers.

Our proprietary KiraLOGIC platform leverages machine learning trained on multiplex-edited CAR-T cells in clinically relevant tumor models to identify synergistic gene-editing combinations. By systematically navigating this complexity, we design therapies optimized for persistence and function in suppressive tumor environments.

KiraGen Bio is committed to translating cutting-edge science into transformative options for patients with limited treatment choices.

Designed to cure. Built to endure.

KiraGen Bio

Org chart

Teams

Offices

KiraGen Bio

Org chart

Teams

Offices

Related companies